A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall ...

Pediatric patients with sickle cell anemia and a history of abnormal cerebral artery velocities had reduced hospitalizations ...

What does it get you? Shares in the two horses who run for the Fakenham Race Club in the green and gold colours, which are as ...

IBS Intelligence (IBSi) is the world’s only pure-play Financial Technology focused research, advisory, and fintech news ...

A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.

Allogene Therapeutics Inc (ALLO) stock saw a decline, ending the day at $2.16 which represents a decrease of $-0.04 or -1.82% from the prior close of $2.2. The stock opened at $2.21 and touched a low ...

The North Platte City Council will hold its first regular meeting of 2025 at 5:30 p.m. in the City Hall council chamber, 211 ...

Jakarta Industry, Trade, Cooperative Small and Medium Enterprise (PPKUKM) Agency Head, Elisabeth Ratu Rante Allo symbolically ...

ALLO Fiber has announced construction will soon begin this spring on a network build in the city of Boulder, Colorado.

Oppenheimer has recently resumed Allogene Therapeutics Inc (ALLO) stock to Outperform rating, as announced on August 8, 2024, according to Finviz. Earlier, on May 31, 2024, Piper Sandler had initiated ...

CNTY-101 is under clinical development by Century Therapeutics and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition ...

Amesanar is under clinical development by RHEACELL and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase II drugs for Diabetic Foot Ulcers does not have sufficient ...